Epilepsy

Published on 02/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1267 times

31 Epilepsy

An epileptic seizure is a transient paroxysm of uncontrolled discharges of neurones causing an event that is discernible by the person experiencing the seizure and/or by an observer. The tendency to have recurrent attacks is known as epilepsy; by definition, a single attack does not usually constitute epilepsy. Epileptic seizures or attacks are a symptom of many different diseases, and the term epilepsy is loosely applied to a number of conditions that have in common a tendency to have recurrent epileptic attacks. A patient with epilepsy will show recurrent epileptic seizures that occur unexpectedly and stop spontaneously.

Epidemiology

There are problems in establishing precise epidemiological information for a heterogeneous condition such as epilepsy. Unlike most ailments, epilepsy is episodic; between seizures, patients may be perfectly normal and have normal investigations. Thus, the diagnosis is essentially clinical, relying heavily on eyewitness descriptions of the attacks. In addition, there are a number of other conditions in which consciousness may be transiently impaired and which may be confused with epilepsy. Another problem area is that of case identification. Sometimes the person may be unaware of the nature of the attacks and so may not seek medical help. People with milder epilepsy may also not be receiving ongoing medical care and so may be missed in epidemiological surveys. Furthermore, since there is some degree of stigma attached to epilepsy, people may sometimes be reluctant to admit their condition. Indeed, epilepsy is still one of the world’s most stigmatised conditions. In today’s society, in both developed and developing countries, fear, misunderstanding, discrimination and social stigma still exist and these affect the quality of life for people with the disorder and their families.

Epilepsy does impact on an individual’s human rights, for example, access to health and life insurance is affected. A person who suffers from epilepsy may not be able to obtain a driving licence and it has an impact on the choice of career. In addition, legislation can impact on the life of individuals with epilepsy, for example, in some countries epilepsy may deter marriages. Legislation based on internationally accepted human rights standards can prevent discrimination and rights violations, improve access to health care services and raise quality of life (WHO, 2009). A global campaign has been established to raise awareness about epilepsy, provide information and highlight the need to improve care and reduce the disorder’s impact through public and private collaboration. This is supported through a partnership established between WHO, the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).

Epilepsy is recognised as a priority in effective health care delivery and there are still a number of issues that health professionals should consider:

Aetiology

Epileptic seizures are produced by abnormal discharges of neurones that may be caused by any pathological process which affects the cortical layer of the brain. The idiopathic epilepsies are those in which there is a clear genetic component, and they probably account for a third of all new cases of epilepsy. In a significant proportion of cases, however, no cause can be determined and these are known as the cryptogenic epilepsies. Possible explanations for cryptogenic epilepsy include as yet unexplained metabolic or biochemical abnormalities and microscopic lesions in the brain resulting from brain malformation or trauma during birth or other injury. The term ‘symptomatic epilepsy’ indicates that a probable cause has been identified.

The likely aetiology of epilepsy depends upon the age of the patient and the type of seizure. The commonest causes in young infants are hypoxia or birth asphyxia, intracranial trauma during birth, metabolic disturbances and congenital malformations of the brain or infection. In young children and adolescents, idiopathic seizures account for the majority of the epilepsies, although trauma and infection also play a role. In this age group, particularly in children aged between 6 months and 5 years, seizures may occur in association with febrile illness. These are usually short, generalised tonic clonic convulsions that occur during the early phase of a febrile disease. They must be distinguished from seizures that are triggered by central nervous system infections which produce fever, for example, meningitis or encephalitis. Unless febrile seizures are prolonged, focal, recurrent or there is a back-ground of neurological handicap, the prognosis is excellent and it is unlikely that the child will develop epilepsy.

The range of causes of adult-onset epilepsy is very wide. Both idiopathic epilepsy and epilepsy due to birth trauma may also begin in early adulthood. Other important causes are head injury, alcohol abuse, cortical dysplasias, brain tumours and cerebrovascular diseases. Brain tumours are responsible for the development of epilepsy in up to a third of patients between the ages of 30 and 50 years. Over the age of 50 years, cerebrovascular disease is the commonest cause of epilepsy, and may be present in up to half of patients.

Pathophysiology

Epilepsy differs from most neurological conditions as it has no pathognomonic lesion. A variety of different electrical or chemical stimuli can easily give rise to a seizure in any normal brain. The hallmark of epilepsy is a rather rhythmic and repetitive hyper-synchronous discharge of neurones, either localised in an area of the cerebral cortex or generalised throughout the cortex, which can be observed on an electroencephalogram (EEG).

Neurones are interconnected in a complex network in which each individual neurone is linked through synapses with hundreds of others. A small electrical current is discharged by neurones to release neurotransmitters at synaptic levels to permit communication with each other. Neurotransmitters fall into two basic categories: inhibitory or excitatory. Therefore, a neurone discharging can either excite or inhibit neurones connected to it. An excited neurone will activate the next neurone whereas an inhibited neurone will not. In this manner, information is conveyed, transmitted and processed throughout the central nervous system.

A normal neurone discharges repetitively at a low baseline frequency, and it is the integrated electrical activity generated by the neurones of the superficial layers of the cortex that is recorded in a normal EEG. If neurones are damaged, injured or suffer a chemical or metabolic insult, a change in the discharge pattern may develop. In the case of epilepsy, regular low-frequency discharges are replaced by bursts of high-frequency discharges usually followed by periods of inactivity. A single neurone discharging in an abnormal manner usually has no clinical significance. It is only when a whole population of neurones discharge synchronously in an abnormal way that an epileptic seizure may be triggered. This abnormal discharge may remain localised or it may spread to adjacent areas, recruiting more neurones as it expands. It may also generalise throughout the brain via cortical and subcortical routes, including collosal and thalamocortical pathways. The area from which the abnormal discharge originates is known as the epileptic focus. An EEG recording carried out during one of these abnormal discharges may show a variety of atypical signs, depending on which area of the brain is involved, its progression and how the discharging areas project to the superficial cortex.

Clinical manifestations

The clinical manifestation of a seizure will depend on the location of the focus and the pathways involved in its spread. An international seizure classification scheme based on the clinical features of seizures combined with EEG data is widely used to describe seizures. It divides seizures into two main groups according to the area of the brain in which the abnormal discharge originates. If it involves initial activation of both hemispheres of the brain simultaneously, the seizures are termed ‘generalised’. If a discharge starts in a localised area of the brain, the seizure is termed ‘partial’ or ‘focal’.

Generalised seizures

Generalised seizures result in impairment of consciousness from the onset. There are various types of generalised seizures.

Partial or focal seizures

Diagnosis

Diagnosing epilepsy can be difficult as it is first necessary to demonstrate a tendency to recurrent epileptic seizures. The one feature that distinguishes epilepsy from all other conditions is its unpredictability and transient nature. The diagnosis of epilepsy is clinical and depends on a reliable account of what happened during the attacks, if possible both from the patient and from an eyewitness. Investigations may help and the EEG is usually one of them. These investigations, however, cannot conclusively confirm or refute the diagnosis of epilepsy.

There are other conditions that may cause impairment or loss of consciousness and which can be misdiagnosed as epilepsy; these include syncope, breath-holding attacks, transient ischaemic attacks, psychogenic attacks, etc. In addition, people may present with acute symptomatic seizures or provoked seizures as a result of other problems such as drug intake, metabolic dysfunction, infection, head trauma or flashing lights (photosensitive seizures). These conditions have to be clearly ruled out before a diagnosis of epilepsy is made. Epilepsy must only be diagnosed when seizures occur spontaneously and are recurrent. The diagnosis must be accurate since the label ‘suffering with epilepsy’ carries a social stigma that has tremendous implications for the person.

The EEG is often the only examination required, particularly in generalised epilepsies, and it aims to record abnormal neuronal discharges. EEGs have, however, limitations that should be clearly understood. Up to 5% of people without epilepsy may have non-specific abnormalities in their EEG recording, while up to 40% of people with epilepsy may have a normal EEG recording between seizures. Therefore, the diagnosis of epilepsy should be strongly supported by a bona fide history of epileptic attacks. Nevertheless, the EEG is invaluable in classifying seizures.

The chance of recording the discharges of an actual seizure during a routine EEG, which usually takes 20–30 min, is slight and because of this, ambulatory EEG monitoring and EEG video-telemetry are sometimes required. Ambulatory EEG allows recording in day-to-day circumstances using a small cassette recorder. EEG video-telemetry is useful in the assessment of difficult cases, particularly if surgery is considered. The person is usually admitted to hospital and remains under continuous monitoring. This is only helpful in a very few cases, and it is best suited for people who have frequent seizures.

Neuroimaging with magnetic resonance imaging (MRI) is the most valuable investigation when structural abnormalities such as stroke, tumour, congenital abnormalities or hydrochephalus are suspected. MRI should be carried out in anyone presenting with partial seizures or where a structural lesion on the brain may be responsible for seizures.

Treatment

National Institute for Health and Clinical Excellence (2004a) issued guidance on the diagnosis and treatment of the epilepsies in adults and children in primary and secondary care. The guidance covered issues such as when a person with epilepsy should be referred to a specialist centre, the special considerations concerning the care and treatment of women with epilepsy and the management of people with learning disabilities. The key points of the guidance are summarised in Box 31.1.

Treatment during seizures

Convulsive seizures may look frightening but the person is not in pain, will usually have no recollection of the event afterwards and is usually not seriously injured. Emergency treatment is seldom necessary. People should, however, be made as comfortable as possible, preferably lying down (ease to the floor if sitting), cushioning the head and loosening any tight clothing or neckwear. During seizures, people should not be moved unless they are in a dangerous place, for example, in a road, by a fire or hot radiator, at the top of stairs or by the edge of water. No attempt should be made to open the person’s mouth or force anything between the teeth. This usually results in damage, and broken teeth may be inhaled, causing secondary lung damage. When the seizure stops, people should be turned over into the recovery position and the airway checked for any blockage.

Partial attacks are usually less dramatic. During automatisms, people may behave in a confused fashion and should generally be left undisturbed. Gentle restraint may be necessary if the automatism leads to dangerous wandering. Attempts at firm restraint, however, may increase agitation and confusion. No drinks should be given after an attack, nor should extra antiepileptic drugs (AEDs) be administered. It is commonly felt that seizures may be life-threatening, but this is seldom the case. After a seizure, it is important to stay with the person and offer reassurance until the confused period has completely subsided and the person has recovered fully.

If a seizure persists for more than 10 min, if a series of seizures occur or if the seizure is particularly severe, then intravenous or rectal administration of 10–20 mg diazepam for adults, with lower doses being used in children, is advisable.

Long-term treatment

In most cases, epilepsy can only be treated by long-term, regular drug therapy. The objective of therapy is to suppress epileptic discharges and prevent the development of epileptic seizures. In the majority of cases, full seizure control can be obtained, and in other patients drugs may reduce the frequency or severity of seizures.

Initiating treatment with an AED is a major event in the life of a person, and the diagnosis should be unequivocal. Treatment options must be considered with careful evaluation of all relevant factors, including the number and frequency of attacks, the presence of precipitating factors such as alcohol, drugs or flashing lights, and the presence of other medical conditions (Feely, 1999). Single seizures do not require treatment unless they are associated with a structural abnormality in the brain, a progressive brain disorder or there is a clearly abnormal EEG recording. If there are long intervals between seizures (over 2 years), there is a case for not starting treatment. If there are more than two attacks that are clearly associated with a precipitating factor, fever or alcohol for instance, then treatment may not be necessary.

Therapy is long-term, usually for at least 3 years and, depending on circumstances, sometimes for life. A full explanation of all the implications must be given to the person and they must be involved in all stages of the treatment plan. It is vital that the person understands the implications of treatment and agrees with the treatment goals. Empowerment of the person with epilepsy to be actively involved in the decision-making process will encourage adherence and is essential for effective clinical management. Support for people so that they understand the implications of the condition and why drug therapy is so important is crucial to ensure effective clinical management.

Health professionals have a key role in supporting people with epilepsy to ensure they are able to manage their medicines appropriately. AED treatment will fail unless the patient fully understands the importance of regular therapy and the objectives of treatment. Poor adherence is still a major factor which results in hospital admissions and poor seizure control and leads to the clinical use of multiple AEDs.

General principles of treatment

Therapy aims to control seizures using one drug, with the lowest possible dose that causes the fewest side effects possible. The established AEDs, carbamazepine, ethosuximide and sodium valproate, are still important parts of the antiepileptic armamentarium. Acetazolamide, clobazam, clonazepam, phenobarbital phenytoin and primidone are also still used. In the last two decades, new AEDs such as vigabatrin, lamotrigine, gabapentin, topiramate, tiagabine, oxcarbazepine, levetiracetam, pregabalin, zonisamide, lacosamide and eslicarbazepine acetate have been introduced. The choice of drugs depends largely on the seizure type, and so correct diagnosis and classification are essential. Table 31.1 lists the main indications for the more commonly used AEDs, and Table 31.2 summarises the clinical use of the newer AEDs.

Table 31.1 Antiepileptic drugs for different seizure types

Seizure type First-linetreatment Second-line treatment
Partial seizures
  Carbamazepine Topiramate
  Lamotrigine Valproate
  Oxcarbazepine Clobazam
  Levetiracetam Zonisamide
    Pregabalin
    Phenytoin
    Gabapentin
    Lacosamide
    Eslicarbazepine
Generalised seizures
Tonic clonic Valproate sodium Lamotrigine
Tonic Carbamazepine Clobazam
Clonic Lamotrigine Phenobarbital
Absence Ethosuximide Clonazepam
Sodium valproate Lamotrigine
Atypical absences Sodium valproate  
Atonic Clonazepam Lamotrigine
Clobazam Carbamazepine
  Phenytoin
  Acetazolamide
  Topiramate
Myoclonic Sodium valproate Levetiracetam
Clonazepam Acetazolamide
  Topiramate

Withdrawal of drugs

AEDs should not be withdrawn abruptly. With barbiturates and benzodiazepines, in particular, rebound seizures may occur. Withdrawal of individual AEDs should be carried out in a slow stepwise fashion to avoid the precipitation of withdrawal seizures (e.g. over 2–3 months). This risk is particularly great with barbiturates, for example, phenobarbital and primidone, and benzodiazepines, for example, clobazam and clonazepam. If a drug needs to be withdrawn rapidly, for example, if there are life-threatening side effects, then diazepam or another benzodiazepine can be used to cover the withdrawal phase.

Examples of withdrawal regimens are given below.

Variations in the above regimens may be used in different settings. People must be monitored closely for any change in seizure frequency. The pace of withdrawal may be slower if the person is within the higher end of the quoted dose range. The pace of withdrawal may be faster if the person is an inpatient.

Newer AEDs

The newer AEDs are generally used as second-line drugs when treatment with established first-line drugs has failed. Exceptions to this are lamotrigine, levetiracetam, topiramate and oxcarbazepine, which have indications for first-line use in the UK. Lamotrigine is considered the first-line option in women of child-bearing potential who have idiopathic generalised epilepsy because of the teratogenic profile of sodium valproate, otherwise the first-line drug for this indication. Oxcarbazepine has the same indications as carbamazepine, although the latter is probably more cost-effective.

There is no evidence that the newer AEDs are more effective than the established drugs, although it could be argued that they might be better tolerated. The chronic side effect profile of the new AEDs has not yet been fully established and this is the main reason why use should be reserved for those cases where benefit outweighs risk. Guidance has been issued that covers the use of the newer AEDs in adults (National Institute for Health and Clinical Excellence, 2004b):

The guidance for adults was followed up by advice for use of the newer AEDs in children (National Institute for Health and Clinical Excellence, 2004c). This advice reflected that issued for adults and included:

A third set of national guidance was issued on the diagnoses and management of the epilepsies in adults and children in primary and secondary care (National Institute for Health and Clinical Excellence, 2004a). A recent report on the implementation of this guidance (National Institute for Health and Clinical Excellence, 2009) revealed:

Chronic epilepsy

The drug treatment of people with established epilepsy that is uncontrolled despite initial attempts is much more difficult than that of newly diagnosed patients. Prognosis is worse, drug resistance may have developed, and there may be additional neurological, psychological or social problems.

Monitoring antiepileptic therapy

Therapeutic drug monitoring (TDM) involves the measurement of serum drug levels and their pharmacokinetic interpretation. It is an integral component in the management of people taking phenytoin and carbamazepine but is less useful in people receiving other AEDs. Indeed, TDM has a very limited use for new AEDs except in people who are acutely unwell, pregnant or elderly. It is also very useful to document AED side effects and in managing drug interactions. Adherence may also be a problem in these patients and hence TDM may be useful to establish adherence with the treatment.

TDM is indicated:

The frequency of undertaking TDM varies. Stabilised patients may require their serum levels to be checked only once or twice a year. TDM may be used more often in some people, for one or more of the above indications. A number of the newer AEDs do not require routine TDM. However, since most are used as adjuvant therapy, it is useful to establish baseline levels of existing drugs before the new agent is introduced. Clinical effects should be monitored and TDM, where appropriate, carried out at 6–12 month intervals.

Drug development and action

The older, more established AEDs were developed in animal models in which the potential drugs were assessed in terms of their ability to raise seizure threshold or prevent spread of seizure discharge. The animals involved in these tests would not have epilepsy but would have seizures induced by, for instance, maximal electroshock or subcutaneous pentylenetetrazole. As a consequence the relevance of these models to epilepsy can be questioned.

Established AEDs such as phenytoin, phenobarbital, sodium valproate, carbamazepine, ethosuximide, clonazepam and diazepam are effective but have poor side effect profiles, are involved in many interactions and have complex pharmacokinetics. Over the past 10–15 years, there has been renewed interest in the development of new AEDs, based on a better understanding of excitatory and inhibitory pathways in the brain. The main mechanisms of current drugs are thought to involve enhancement of the inhibitory GABA-ergic system, for example, benzodiazepines, barbiturates, tiagabine, vigabatrin or use-dependent blockers of sodium channels, for example, carbamazepine, oxcarbazepine, lamotrigine and phenytoin (Fig. 31.1).

New drugs include lamotrigine, pregabalin, levetiracetam, topiramate, felbamate, lacosamide, oxcarbazepine, eslicarbazepine and zonisamide. Unlike most of the older agents, vigabatrin, lamotrigine, levetiracetam, lacosamide, gabapentin, pregabalin and zonisamide are devoid of clinically significant enzyme-inhibiting or enzyme-inducing properties. Oral contraceptives may increase the metabolism of lamotrigine and topiramate, and oxcarbazepine may induce cytochrome P450 CYP3A4 which is responsible for the metabolism of oral contraceptives (Sabers and Gram, 2000).

AED profiles

The maintenance doses for the more widely used AEDs are given in Table 31.3, while their pharmacokinetic profile is presented in Table 31.4. Drug interactions are summarised in Table 31.5, and common side effects in Table 31.6.

Table 31.6 Side effect profile of antiepileptic drugs

Drug Dose related (predictable) Non-dose related (idiosyncratic)
Carbamazepine Diplopia, drowsiness, headache, nausea, orofacial dyskinesia, arrhythmias Photosensitivity, Stevens–Johnson syndrome, agranulocytosis, aplastic anaemia, hepatotoxicity
Clonazepam Fatigue, drowsiness, ataxia Rash, thrombocytopenia
Ethosuximide Nausea, vomiting, drowsiness, headache, lethargy Rash, erythema multiforme, Stevens–Johnson syndrome
Gabapentin Drowsiness, diplopia, ataxia, headache Not reported
Lacosamide Nausea, vomiting, dizziness, headache, drowsiness, depression, diplopia (double vision), impaired memory, impaired coordination, tremor, fatigue (tiredness), asthenia (muscle weakness), pruritus (itching). Not reported
Lamotrigine Headaches, drowsiness, diplopia, ataxia Liver failure, disseminated intravascular coagulation
Levetiracetam Dizziness, drowsiness, irritability, behavioural problems, insomnia, ataxia (unsteadiness), tremor, headache, nausea Not reported
Oxcarbazepine Diplopia (double vision), ataxia (unsteadiness), headache, nausea, confusion and vomiting Skin rash
Phenobarbital Fatigue, listlessness, depression, poor memory, impotence Maculopapular rash, exfoliation, hepatotoxicity hypocalcaemia, osteomalacia, folate deficiency
Phenytoin Ataxia, nystagmus, drowsiness, gingival hyperplasia, hirsutism, diplopia, asterixis, orofacial dyskinesia, folate deficiency Blood dyscrasias, rash, Dupuytren’s contracture, hepatotoxicity
Sodium valproate Dyspepsia, nausea, vomiting, hair loss, anorexia, drowsiness Acute pancreatitis, aplastic anaemia, thrombocytopenia, hepatotoxicity
Tigabine   Dizziness, fatigue (tiredness), nervousness, tremor, concentration difficulties, depression of mood, agitation
Topiramate Dizziness, drowsiness, nervousness, fatigue, weight loss Not reported
Vigabatrin Drowsiness, dizziness, weight gain Behavioural disturbances, severe psychosis
Zonisamide Ataxia, dizziness, somnolence, anorexia Hypersensitivity, weight decrease, rash, gastro-intestinal problems

Carbamazepine

Carbamazepine is a drug of first choice in tonic clonic and partial seizures, and may be of benefit in all other seizure types except generalised absence seizures and myoclonic seizures. Tolerance to its beneficial effect does not usually develop. Adverse events may occur in up to a third of patients treated with carbamazepine but only about 5% of these events will require drug withdrawal, usually due to skin rash, gastro-intestinal disturbances or hyponatraemia. Dose-related adverse reactions including ataxia, dizziness, blurred vision and diplopia are common. Serious adverse events including hepatic failure and bone marrow depression are extremely uncommon.

Carbamazepine exhibits autoinduction, that is, induces its own metabolism as well as inducing the metabolism of other drugs. It should, therefore, be introduced at low dosage and this should be steadily increased over a period of a month. The target serum concentration therapeutic range is 4–12 μcg/mL. In addition, a number of clinically important pharmacokinetic interactions may occur, and caution should be exercised when co-medication is instituted (see Table 31.5). For patients requiring higher doses, the slow-release preparation of carbamazepine has distinct advantages, allowing twice-daily ingestion and avoiding high peak serum concentrations. A ‘chewtab’ formulation is also available and pharmacokinetic studies have shown that it performs well even if inadvertently swallowed whole. Carbamazepine retard offers paediatric patients in particular a dosage form that reduces fluctuations in the peak to trough serum levels and hence allows a twice-daily regimen, which can assist compliance.

Sodium valproate

Sodium valproate is a drug of first choice for the treatment of generalised absence seizures, myoclonic seizures and generalised tonic clonic seizures, especially if these occur as part of the syndrome of primary generalised epilepsy. Tolerance to its anti-epileptic action does not usually occur. Drug interactions with other AEDs may be problematic. Phenobarbital levels increase following co-medication with valproate, and a combination of these two drugs may result in severe sedation. Sodium valproate may also inhibit the metabolism of lamotrigine, phenytoin and carbamazepine. Enzyme-inducing drugs enhance the metabolism of sodium valproate, so caution should be exercised when other AEDs are introduced or withdrawn.

Up to a third of patients may experience adverse effects, but fewer than 5% will require the drug to be stopped. Adverse effects include anorexia, nausea, diarrhoea, weight gain, alopecia, skin rash and thrombocytopenia. Confusion, stupor, tremor and hyper-ammonaemia are usually dose related. Serious adverse events, including fatal pancreatic and hepatic failure, are extremely uncommon. In children under 2 years, on other AEDs and with pre-existing neurological deficit, the risk of this is 1/500. In adults on valproate monotherapy, the risk is 1/37,000.

The usual therapeutic range quoted is 50–100 μcg/mL, although because of the lack of a good correlation between total valproate concentrations and effect, serum level monitoring of the drug has limited use. TDM should only be performed in cases of suspected toxicity, deterioration in seizure control, to check adherence or to monitor drug interactions. Routine monitoring of this drug is not necessary. Sodium valproate is more teratogenic than other commonly used AEDs and should be used cautiously in women of child-bearing age.

Zonisamide

Zonisamide, a sulphonamide analogue which inhibits carbonic anhydrase, is a potent blocker of the spread of epileptic discharges. This effect is believed to be mediated through action at voltage-sensitive sodium channels.

It is used as a second-line drug for patients with partial seizures with or without secondary generalisation. Anecdotal reports of its efficacy in other seizure types, particularly myoclonic seizures, need to be formally tested. Recommended doses are between 200 and 500 mg/day, although some patients may derive benefit from doses outside this range. The recommended starting dose for most patients is 100 mg once daily, titrating upwards every 2 weeks in 100 mg/day increments until seizure control is achieved or side effects develop. Its long elimination half-life allows once-daily dosing.

Zonisamide does not affect levels of carbamazepine, barbiturates or valproate, but may increase the serum concentration of phenytoin by about 10–15%. Zonisamide metabolism is, however, induced by carbamazepine, barbiturates and phenytoin and higher zonisamide doses may be necessary during co-administration with these AEDs.

Side effects of zonisamide include dizziness, drowsiness, headaches, hyporexia, nausea and vomiting, weight loss, skin rashes, irritability, impaired concentration and fatigue. These are mostly transient and seem to be related to the dose and rate of titration. Nephrolithiasis has also been reported, particularly in caucasians. It is not recommended for women of child-bearing age as there are issues about its teratogenic potential (Table 31.7).

Table 31.7 Common therapeutic problems in epilepsy

Problem Comment
Hepatic enzyme induction Enzyme induction occurs with carbamazepine, phenytoin, phenobarbital, primidone and topiramate
Interactions occur with a large number of drugs including oral contraceptives
Use of progesterone-only contraceptives with enzyme-inducing antiepileptic drug Best avoided. If no acceptable alternative, patient should take at least double usual dose of progesterone-only pill
Use of combined oral contraceptive with enzyme-inducing antiepileptic drug Preparations containing 50 μcg of oestrogen should be used
Continuation of antiepileptic drug during pregnancy Ideally review before attempting pregnancy to determine if reducing or discontinuing treatment is possible
Use of phenytoin as monotherapy Less frequently considered first-line monotherapy due to poor side effect profile, narrow therapeutic index and saturation pharmacokinetics
Prescribing of branded antiepileptic drugs Debate continues about whether significant differences exist between generic and branded antiepileptic drugs

Evidence for clinical use of newer drugs

The evidence for the efficacy, tolerability, and safety of seven new AEDs (gabapentin, lamotrigine, topiramate, tiagabine, oxcarbazepine, levetiracetam and zonisamide) in the treatment of children and adults with refractory partial and generalised epilepsies was assessed by French et al. (2004). All drugs demonstrated efficacy as add-on therapy in patients with refractory partial epilepsy. The relative efficacy of the various agents could not, however, be determined due to the differing populations and dose ranges employed in the various studies. The analysis did, however, show that for all drugs, efficacy and side effects increased with increasing dose. A slower titration of dosage improved tolerability and hence the guidance remains to start with a low dose and increase slowly until side effects occur. For efficacy it appears useful to push to maximal tolerated dose.

Wilby et al. (2005) evaluated the clinical effectiveness, tolerability and cost-effectiveness of gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate and vigabatrin for epilepsy in adults. They included randomised controlled trials (RCTs) and systematic reviews for the newer AEDs when used in the treatment of adults with newly diagnosed or refractory epilepsy and relevant comparator studies which employed older AEDs, other newer AEDs and placebo. The overall findings revealed the following:

Case studies

References

Berg A.T., Berkovic S.F., Brodie M.J., et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51:676-685.

Duncan J.S., Sander J.W., Sisodiya S.M., et al. Adult epilepsy. Lancet. 2006;367:1087-1100.

Feely M. Drug treatment of epilepsy. Br. Med. J.. 1999;318:106-109.

French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy. Epilepsia. 2004;45:410-423.

National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, Clinical Guideline 20. London: NICE. 2004. Available at: http://www.nice.org.uk/page.aspx?o=CG020&c=cns

National Institute for Health and Clinical Excellence. New drugs for epilepsy in adults, Technology Appraisal 76. London: NICE. 2004. Available at: http://www.nice.org.uk/download.aspx?o=ta076guidance

National Institute for Health and Clinical Excellence. Newer drugs for epilepsy in children, Technology Appraisal 76. London: NICE. 2004. Available at: http://www.nice.org.uk/page.aspx?o=ta079guidance

National Institute for Health and Clinical Excellence. Implementation uptake report: the epilepsies, the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: NICE; 2009. Available at: http://www.nice.org.uk/media/250/28/ImpUptakeReportCG20.pdf

Sabers A., Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs. 2000;60:23-33.

WHO. Epilepsy, Key Facts. Fact Sheet Number 999. Available at: http://www.who.int/mediacentre/factsheets/fs999/en/, 2009.

Wilby J., Kainth A., Hawkins N., et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technology Assessment. 9(15), 2005. Available at: http://www.hta.ac.uk/1304